The economics of indication-based drug pricing

New England Journal of Medicine

Volumn 377, Issue 2, 2017, Pages 103-106

  Chandra, Amitabh ^a   Garthwaite, Craig ^b  

^a HARVARD UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; PRESCRIPTION DRUG;

DRUG COST; DRUG INDICATION; DRUG THERAPY; HUMAN; PHARMACEUTICAL CARE; PRIORITY JOURNAL; REVIEW; COST CONTROL; DRUG INDUSTRY; ECONOMIC ASPECT; ECONOMICS; FEE; PROCEDURES; UNITED STATES;

COST CONTROL; DRUG COSTS; DRUG INDUSTRY; ECONOMIC COMPETITION; FEES, PHARMACEUTICAL; HUMANS; PRESCRIPTION DRUGS; UNITED STATES;

EID: 85026320674     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1705035     Document Type: Review

References (5)

1. Bach PB. Indication-specific pricing for cancer drugs. JAMA 2014; 312: 1629-30.
2. Pearson SD, Dreitlein B, Henshall C. Indication-specific pricing of pharmaceuticals in the United States health care system: A report from the 2015 ICER Membership Policy Summit. Boston: Institute for Clinical and Economic Review, March 2016 (https://icer-review.org/wp-content/uploads/2015/03/Final-Report-2015-ICER-Policy-Summit-on-Indication-specific-Pricing-March-2016-revised-icons-002.pdf).
3. Rockoff JD. How Pfizer set the cost of its new drug at 9, 850 a month. Wall Street Journal. December 9, 2015 (https://www.wsj.com/articles/the-Art-of-setting-A-drug-price-1449628081).
4. Dickson V. As insurers limit access to hep C drugs, patients and doctors bristle. Modern Healthcare. May 20, 2015 (http://www.modernhealthcare.com/article/20150520/NEWS/150519897).
5. Stern AD, Alexander BM, Chandra A. How economics can shape precision medicines. Science 2017; 355: 1131-3.